Recognition of inter-transmembrane regions of acetylcholine receptor α subunit by antibodies, T cells and neurotoxins implications for membrane-subunit organization  by Atassi, M.Zouhair et al.
Volume 228, number 2, 295-300 FEB 05475 February 1988 
Recognition of inter-transmembrane r gions of acetylcholine 
receptor a subunit by antibodies, T cells and neurotoxins 
Implications for membrane-subunit organization 
M. Zouhair Atassi, Taghi Manshouri and Tsuyoshi Yokoi 
Marrs McLean Department of Biochemistry, Baylor College of Medicine, Houston, TX 77030, USA 
Received 12 November 1987 
Three regions of the a chain of Torpedo californica cetylcholine receptor (AChR), corresponding to residues ~262-276, 
a388408 and a427437 were synthesized, purified and characterized. The first two peptides have been proposed to occupy 
inter-transmembrane regions while the third represented the C-terminal segment, proposed by various models to be either 
extracellular or intracellular. Peptide a388408 stimulated a good response in the AChR-primed T cells of H-2$ haplotype 
mice, a low response in the H-2s haplotype and no response in the H-2b haplotype. Peptide a427437 stimulated AChR- 
primed T cells of the H-2s haplotype, but caused no response in the q and b haplotypes. Peptide 1x262-276 evoked no 
in vitro stimulation in any of the s, q or b haplotypes. In antibody binding studies, peptide a388408 bound antibodies 
raised against free AChR or against membrane-bound AChR. The other two peptides showed little or no binding activity. 
Further, peptide a388408 bound specifically both 1Z5-I-labelled bungarotoxin and cobratoxin, while the other two 
peptides had no binding activity. These results were consistent with only one of the models for subunit organization with- 
in the membrane. 
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1. INTRODUCTION 
The nicotinic acetylcholine receptor (AChR) 
plays a central role in post-synaptic neuromuscular 
transmission. In response to binding of 
acetylcholine [l-4], the receptor mediates ion flux 
across the cell membrane. This regulatory activity 
is inhibited by binding of cr-neurotoxin to the 
AChR LY subunit [5] or by some anti-receptor an- 
tibodies. The receptor is a pentamer comprising 
four subunits (c&$). The primary structures of 
all four AChR subunits of Torpedo californica 
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have been deduced from the respective cDNA se- 
quences [6-81. It was possible to identify the ex- 
tracellular part of the chain [8-lo] and four 
transmembrane hydrophobic regions intercon- 
nected by two short peptide segments on the ex- 
tracellular side of the membrane. In the present 
work, we have synthesized the two inter- 
transmembrane regions ~262-276 and (~388-408 
as well as the C-terminal segment a427-437 and 
have determined their ability to bind a-neurotoxins 
(BgTX and CbTX) and antibodies against free 
AChR and membrane-bound AChR and to 
stimulate the in vitro proliferation of AChR- 
primed T lymphocytes. 
2. MATERIALS AND METHODS 
Abbreviations: AChR, the acetylcholine receptor molecule; The preparation of AChR from the electric organ tissue of T. 
BgTX, cu-bungarotoxin; CbTX, cobratoxin; PBS, 0.01 M colifornicu (Pacific Bio-Marine Laboratories) was carried out as 
sodium phosphate buffer, pH 7.2, in 0.15 M NaCl; Con A, described [11,12]. The AChR preparations had an cr- 
concanavalin A; BSA, bovine serum albumin bungarotoxin binding activity of 8.7-9.1 nmol/mg AChR. 
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Table 1 
Proliferative responses of lymph node cells from mice primed with AChR to in vitro challenge with peptides or with AChR 
Proliferative response (A cpm & SD) of different mouse strainsa 
Mouse strain: SJL (H-2”) SWR (H-2q) C57BL/6 (H-2b) 
A cpm Opt. doseb A cpm Opt. doseb A cpm Opt. doseb 
kg/ml) lug/ml) &g/ml) 
Challenge antigen 
Peptide ~262-276 337 f 90 40 447 f 55 20 128 f 30 20 
Peptide ~~388-408 9854 Z!Z 580 20 2490 k 440 20 552 f 66 80 
Peptide ~~427-437 9029+ 601 20 537 i 15 20 408 + 40 40 
Controls 
AChRC 108972 f 7100 2.5 77952 i 5510 2.5 48985 * 6063 2.5 
Peptide (~146-162’ 72015 f 3600 80 18478 + 1130 80 35595 * 3240 80 
Con A 314136 4 18850 409852 f 13360 205 270 f 743 1 
Ovalbumin 992 f 365 0 nd 
Lysozyme 0 157 * 80 0 
a Note that unchallenged T cells incorporated the following cpm of [‘Hlthymidine (medium background): SJL, 2244 * 135 cpm; SWR, 
2700 * 50 cpm; C57BL/6, 1105 + 66 cpm 
b Studies were carried out in the dose range l-100 rg/ml. The table summarizes the maximum proliferative response obtained at the 
indicated optimum dose 
’ AChR and peptide ~146-162, previously shown to stimulate AChR primed T cells in these strains [23], were used here as positive 
controls to confirm that the T cells were responding correctly 
The peptide regions studied were: ~~262-276, Glu-Leu-Ile- 
Pro-Ser-Thr-Ser-Ser-Ala-Val-Pro-Leu-Ile-Gly-Lys(Gly); cu388- 
408, Ser-Asp-Glu-Glu-Ser-Ser-Asn-Ala-Ala-Glu-Glu-Trp-Lys- 
Tyr-Val-Ala-Met-Val-Ile-Asp-His(Gly); cr427-437, Ala-Gly- 
Arg-Leu-Be-Glu-Leu-Ser-Gln-Glu-Gly. The peptides were syn- 
thesized on a Gly-resin by the Merrifield solid phase method 
[13] as described [14]. They were purified by gel filtration on 
Sephadex G-25 (Pharmacia Fine Chemicals) in 0.05 M 
triethylamine followed by ion exchange chromatography on 
CM-Sephadex or DEAE-Sephadex [15-171. Peptide 
homogeneity and amino acid analysis were examined as de- 
scribed [18,19]. 
Rabbit and outbred mouse antibodies against soluble AChR 
or against membrane-bound AChR were prepared as described 
[12]. The antisera used in the present studies were obtained 57 
days after the initial injection with free receptor immunization 
and at 42 days in the case of membrane-bound AChR. The IgG 
fraction of the antisera were prepared as described [17]. 
Quantitative adsorbent titrations of ‘ZSI-labelled BgTX, 
CbTX or immune IgG were done as described [20]. Adsorbents 
Table 2 
Binding of anti-AChR antibodies to AChR and to the peptides 
Adsorbent Antibodies bound (A cpm) 
Antibodies against free AChR Antibodies against membrane-bound 
AChR 
Rabbit Mouse Mouse Mouse Mouse Mouse Mouse 
antiserum antiserum 43 antiserum 40 antiserum 41 antiserum 51 antiserum 54 antiserum 55 
AChR 115980 189970 201230 212200 121040 110460 179670 
Peptides 
~262-276 1910 480 2120 1112 474 170 1040 
~388-408 10410 41233 28 550 49811 20970 9680 25 040 
(~427-437 1280 370 0 720 652 220 1150 
Values were obtained by double antibody titrations as described in the text and in the legend of fig. 1. Results represent he average 
of 6 replicate analyses (using 100 /tl of a 1: 1, v/v, adsorbent suspension) which varied f 1.3% or less. The values have been corrected 
for non-specific binding (k 3% or less) to uncoupled Sepharose and adsorbents of BSA, sperm whale myoglobin, hen lysozyme, 
ovalbumin, a nonsense peptide [20] and hemoglobin (Y chain synthetic peptides 41-55, 51-65 and 45-60 [21] 
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of unrelated proteins (BSA, sperm whale myoglobin, hen 
lysozyme, ovalbumin) and unrelated synthetic peptides 120,211 
were used as controls for non-specific binding. AChR was 
coupled as described recently [12]. Also, the binding to AChR 
peptides, of antibodies against unrelated proteins (myoglobins, 
lysozymes, ragweed allergen Ra3) served as additional controls. 
Antibody binding was also determined by double-antibody 
solid-phase titrations [22] using 12~I-labelled rabbit anti-mouse 
IgG and mouse anti-rabbit IgC to monitor the binding of the 
respective unlabelled anti-AChR antibodies. The specificity of 
binding of ‘Z51-labelled toxin to peptide adsorbents was coti- 
firmed by inhibition with unlabelled toxin. 
The ability of the three peptides to stimulate the in vitro pro- 
liferation of T cells from AChR-primed mice was examined in 
four mouse strains. Two of the strains (SJL, H-2S and SWR, 
H-2q) are high responders to AChR, one strain (C57BL/6, 
H-2b) is an intermediate responder and one strain (C3H/He, 
H-2k) is a non-responder [23]. Peptide (u146- 162 was used as a 
control because all three strains respond to this peptide [23]. 
The optimum immunizing AChR dose and the procedures for 
immunization, cell harvesting, culture, in vitro challenge with 
AChR or peptides and pulsing with [3H]thymidine were per- 
formed as described [23]. 
3. RESULTS 
3.1. Purification and characterization of the 
synthetic peptides 
After purification, the synthetic peptides were 
homogeneous by peptide mapping [ 181. In amino 
acid analysis, the synthetic peptides had composi- 
tions which were in agreement with those expected 
from their sequence. Their amino acid composi- 
tions (with the values expected from the sequence 
in parentheses) were: peptide tu262-276, Thr, 
1.01(l); Ser, 3.00(3); Glu, 1.02(l); Pro, 1.94(2); 
Gly, 2.02(2); Ala, 1.02(l); Val, 0.99(l); Ile, 
2.03(2); Leu, 2.04(2); Lys, 0.99(l); peptide 
a388-408, Asp, 3.07(3); Ser,2.96(3); Glu, 4.20(4); 
Gly, 1.12(l); Ala, 3.20(3); Val, 1.93(2); Met, 
1.07(l); Ile, 0.99 (1); Tyr, 0.95(l); His, 0.88(l); 
Lys, 1.04(l); Trp, 0.86(l); peptide &427-437, Ser, 
0.94(l); Glu/Gln, 3.2(3); Gly, 2.13(2); Ala, 
1.18(l); Be, 1.00(l); Leu, 2.08(2); Arg, 0.97(l). 
3.2. Proliferation of AChR-primed T cells in 
response to peptides 
The responses of T cells from three AChR- 
primed mouse strains are summarized in table 1 
which gives the data at the optimum challenge 
doses for the respective proteins and peptides. Im- 
munization of SJL with native AChR gave T cells 
which responded strongly to AChR, and to pep- 
tides a388-408 and ~~427-437, but mounted no 
Adsorbent Volume (,uI) 
Fig. 1. Radioimmunoadsorbent double-antibody titrations of 
anti-AChR antibodies with peptide adsorbents. (A) Binding of 
antibodies in mouse antiserum (No.43) against free AChR. (B) 
Binding of antibodies in mouse antiserum (No.51) against 
membrane-bound AChR. Constant amounts of mouse anti- 
AChR antisera (20 ~1, pre-diluted 1: 500, v/v) were incubated 
with varying amounts of peptide or protein adsorbents. After 
washing, the adsorbents were incubated with a fixed amount of 
%labelled rabbit anti-mouse Igcf: Binding studies were done 
in O.lVo BSA in PBS at a constant reaction volume of 250~1. 
The adsorbents were: (A) AChR; (A) peptide (~388-408; (0) 
peptide ~~262-276; (0) peptide (~427-437; (u) peptide 
(~182-198, previously shown to bind anti-AChR antibodies 
[12,14] and used here as a positive control. These antibodies did 
not bind to any unrelated control proteins and peptides and 
conversely antibodies against unrelated proteins (see text) did 
not bind to any of the AChR peptides. The binding curves of 
these controls superimposed with those of peptides ~262-276 
and (r427-437. 
significant response to peptide ~262-276. Cells 
from AChR-primed SWR mice gave the expected 
[23] responses to AChR and to peptide ~146-162, 
and also responded weakly to peptide ~388-408 
but did not respond to peptides ~262-276 and 
(~427-437 (table 1). T cells from AChR-primed 
mouse strains, C3H/He and C57BL/6, gave the 
expected responses [23] to AChR and to peptide 
(~146-162, but did not respond to any of the three 
peptides ~~262-276, ~~388-408 and a427-437. The 
specificity of the stimulation by the AChR peptides 
was confirmed by absence of stimulation by 
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Fig.2. Binding of ‘ZSI-labelled toxins to AChR and peptides. (A) 
Binding of BgTX; (B) binding of CbTX. Fixed volumes (25 pl 
of 1: 1 suspension) of each adsorbent were reacted (16 h, room 
temperature) in triplicate, with increasing amounts of ‘2JI- 
labelled toxin in a final reaction volume of 60 ~1 of 0.1% BSA 
in PBS. After washing 5 times in the centrifuge with PBS, the 
tubes were counted. (A) AChR; (A) peptide (~388-408; (0) 
peptide ~262-276; (0) peptide (~427-437; (m) peptide 
cy182-198, previously shown [35] to bind BgTX and CbTX and 
used here as a positive control. Note that adsorbents of several 
unrelated proteins and peptides (see text) did not bind toxins 
giving binding curves that superimposed with that of peptide 
~262-276. 
unrelated proteins and peptides. Conversely, 
AChR or its peptides did not stimulate prolifera- 
tion of T cells from mice that had been immunized 
with unrelated proteins (myoglobin and ovalbu- 
min) and peptides (not shown). The viability of the 
cells in all these studies was indicated from their 
responses to Con A, PPD and LPS. 
3.3. Antibody binding studies 
Radioimmunoadsorbent titrations were per- 
formed both by direct binding of 1251-labelled anti- 
AChR antibodies and by a double-antibody assay 
using a fixed amount of antibody and increasing 
amounts of adsorbents (see fig.1, for example). 
The results in table 2 summarize the mean binding 
values obtained by the double-antibody assay, and 
show that peptide (~388-408 binds a considerable 
298 
fraction of anti-AChR antibodies with antisera 
against free AChR as well as with antisera against 
membrane-bound AChR. The other two peptides 
showed little or no binding activity with these an- 
tisera. 
3.4. Binding of ‘251-labelled toxins to the peptides 
The binding of BgTX to adsorbents of the pre- 
sent synthetic peptides and appropriate controls 
[13] was determined by titrating a fixed amount of 
‘251-labelled BgTX and CbTX with varying 
amounts of peptide adsorbents. Binding studies 
were also carried out using a fixed amount of ad- 
sorbent and increasing amounts of ‘251-labelled 
CbTX and BgTX. In titration of the present hree 
peptides with radiolabelled CbTX and BgTX, only 
peptide a388-408 bound toxin (fig.2). The 
negative (i.e., no binding activity) and positive 
control proteins and peptides gave the expected 
binding results. The specificity of toxin binding to 
peptide (~388-408 was confirmed by inhibition 
studies. The binding of labelled toxins to the pep- 
tide was inhibited almost completely by unlabelled 
toxin (fig.3), whereas other unrelated proteins had 
no inhibitory effect, even at much higher concen- 
‘1 
L;M 
0 -9 -8 -7 -6 
bg Inhibitor (M) 
-5 
Fig.3. Inhibition by unlabelled BgTX of the binding of “‘I- 
labelled BgTX to peptide a388-408. Constant volumes of 
peptide adsorbent (10 ~1 of 1: 1 suspension, v/v) were incubated 
(4 h, room temperature) with increasing concentrations of 
unlabelled BgTX or control proteins, followed by the addition 
of ‘ZSI-labeIled BgTX (2 x 10’ cpm) and a further incubation 
for 14 h at room temperature. The reaction was done in 
triplicate in 0.1% BSA in PBS and a reaction volume of 35 ~1. 
After reaction, the adsorbents were washed 5 times with PBS 
and counted. (A) Inhibition by unlabelled BgTX; (0) inhibition 
by unrelated control proteins (BSA, sperm whale myoglobin, 
lysozyme and ovalbumin). Note that the,amount of ‘ZSI-labelled 
BgTX bound to uninhibited peptide adsorbent was 4760 cpm. 
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trations than the toxin inhibitor. The ICSO for toxin 
binding to peptide a388-408 was 6.7 x 10e6 M. 
4. DISCUSSION 
Knowledge of the organization of the polypep- 
tide chains of AChR in the cell membrane is 
valuable for the understanding, in molecular 
terms, of the mechanism of the biological function 
of AChR. Three models have been proposed for 
the folding of AChR subunits in the cell mem- 
brane. One model [8,9] proposed four transmem- 
brane regions (Ml to M4). In the second model 
[24,25], a fifth transmembrane region (MS) was 
postulated, while the third model [26] envisioned 
seven transmembrane regions. In the first two 
models, the entire region l-210 was proposed to 
be extracellular, while in the third model, the 
region comprising residues 142-192 was made into 
two transmembrane segments. 
Recently, by applying a comprehensive synthetic 
strategy [27], uniform-sized overlapping synthetic 
peptides representing the entire region l-210 of 
the cy chain were studied for their ability to activate 
AChR-primed T cells [23] and to bind anti-AChR 
antibodies [12] (made against free AChR and 
against membrane-sequestered AChR) and neuro- 
toxins [ 19,281. These studies [ 141 helped to dismiss 
the third model [26], but were unable to differen- 
tiate between the first two models, because in both 
models residues l-210 are extracellular. The two 
models were also in agreement by placing the 
region 262-276 on the extracellular side of the 
membrane interconnecting transmembrane regions 
M2-M3. The two models, however, differed in the 
placement of the C-terminal segment 427-437. 
Additionally, in the first model, the region 
388-408 is intracellular while in the second model, 
this region is extracellular connecting transmem- 
brane regions M4 (residues 409-425) and M5 
(residues 365-387). Thus, it was decided to syn- 
thesize the regions (~262-276 (linking extracellular- 
ly M2 and M3, in both models), a388-408 (linking 
M4 and MS extracellularly in the second model, 
but is intracellular in the first model) and the C- 
terminal rx427-437. Should one, or more, of these 
peptides activate AChR-primed T cells, bind an- 
tibody or, most importantly, bind cu-neurotoxin it 
might then be possible to deduce the appropriate 
disposition of that region. Obviously, absence of 
activity will not be informative. 
The finding that the peptide ~~388-408 bound 
antibodies against soluble AChR and against 
AChR bound to membrane vesicles indicated that 
this region is accessible to the immune system and 
is not buried in the membrane. Its accessibility to 
the immune system was further supported by its 
ability to stimulate the in vitro proliferation of 
AChR-primed T cells. The finding that the C- 
terminal region ~427-437 was recognized by T 
cells and not by antibodies is not unusual and has 
been observed with other regions on the AChR CY 
chain [23] and with other proteins [29-331. The 
dependence of T-cell recognition on the mouse 
straih is indicative of Ir gene control operating at 
the antigenic site level [34]. At any rate, the im- 
munological findings indicate that the_:regions 
a388-408 and ~~427-437 are not transmembrane, 
but do not permit the choice of whether they are 
extracellular or intracellular. 
Although the binding activity of peptide 
&388-408 for BgTX and CbTX was considerably 
lower than that of peptide a182-198, it was never- 
theless significant and specific. The ability of pep- 
tide ~388-408 to bind cu-neurotoxin will enable the 
localization of this region on the extracellular side 
of the cell membrane. It is not unreasonable to 
assume that intracellular parts of the a chain will 
have no functional requirement, and hence will not 
be expected, to bind a-neurotoxin. The localiza- 
tion of the region a388-408 on the extracellular 
side of the membrane would enable the choice be- 
tween the two organizational models which 
postulate either four transmembrane regions [8,9] 
or five transmembrane regions [24,25]. Our results 
are consistent with the latter model [24,25] in 
which this region is depicted as extracellular. 
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